PoliticalRepoPoliticalRepo

United States · Bill · S

S. 252 (115th)

Medicare Drug Savings Act of 2017

Original

referredUnited States· United States Congress· EN

Introduced

1 February 2017

Last action

1 February 2017 · Introduced

Status

Read twice and referred to the Committee on Finance.

Sponsors

Rep. Nelson, Bill [D-FL-11], Sen. Leahy, Patrick J. [D-VT], Rep. Durbin, Richard J. [D-IL-20], Sen. King, Angus S., Jr. [I-ME], Sen. Reed, Jack [D-RI], Sen. Blumenthal, Richard [D-CT], Sen. Brown, Sherrod [D-OH], Sen. Stabenow, Debbie [D-MI], Sen. Sanders, Bernard [I-VT], Sen. Baldwin, Tammy [D-WI], Sen. Hirono, Mazie K. [D-HI], Sen. Udall, Tom [D-NM], Sen. Franken, Al [D-MN], Sen. Klobuchar, Amy [D-MN], Sen. Whitehouse, Sheldon [D-RI], Sen. Shaheen, Jeanne [D-NH]

Subjects

Healthcare

Source updated

11 August 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Medicare Drug Savings Act of 2017 This bill requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for prescription drugs dispensed to eligible low-income individuals under the Medicare prescription drug benefit or a Medicare Advantage (MA) prescription drug plan (PDP). Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 1 February 2017

    Introduced

    Read twice and referred to the Committee on Finance.

    Source: IntroReferral

  2. 1 February 2017

    Introduced

    Introduced in Senate

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.